The effect of medical cannabis on cognitive functions: a systematic review

Abstract

Background Cannabis-based medicines are widely used in the treatment of a number of medical conditions. Unfortunately, cognitive disturbances are often reported as adverse events, although conversely, cognitive improvements have been reported. Hence, the objective of the present study was to identify, critically appraise and synthesise research findings on the potential impact of cannabis-based medicines on cognitive functioning. Methods Four databases (EMBASE, PsycINFO, PubMed and Scopus) were systematically searched. Studies were included if they provided findings on the impact of cannabis-based medicines in controlled settings on cognitive functioning measured by recognised cognitive tests in human adults. Study participants were required to be their own case-control, and neither studies on abuse, abstinences, patients with severe neurodegenerative diseases nor cancer-related pain conditions were included. Screening, risk of bias assessment and data extraction were conducted independently by two researchers. Findings were tabulated and synthesised by outcome. Findings Twenty-three studies were included, comprising a total of N = 917. Eight studies used Sativex as the cannabis-based medicine two used Epidiolex, two other studies used sprays, three studies used gelatine capsules, five smoked cannabis, two other and finally one studied cannabis withdrawal. Fifteen studies reported non-significant findings; six reported cognitive impairments; one study found cognitive improvement and a single study found improvement following withdrawal. Thirteen studies had cognitive or neuropsychological functioning as the primary outcome. Conclusions Due to a large heterogeneity and methodological limitations across studies, it is not possible to make any definite conclusions about the impact of cannabis-based medicines on cognitive functioning. However, the majority of high-quality evidence points in the direction that the negative impact of cannabis-based medicines on cognitive functioning is minor, provided that the doses of THC are low to moderate. On the other hand, long-term use of cannabis based medicines may still adversely affect cognitive functioning. In the studies that found impaired cognitive functioning to be significant, all of the test scores were either within the normal range or below what would be characterised as a neuropsychologically cognitive impairment.

Brain-Derived Neurotrophic Factor Levels in Cannabis Use Disorders - A Systematic Review and Meta-Analysis

“…THC, the psychoactive component in cannabis known for the "high," on the other hand, has been linked to deleterious effects on cognitive function and memory [ 27 ]. Multiple studies have reported a wide range of CNS effects on the administration of THC [ 28 , 29 ].…”

Should oncologists trust cannabinoids?

“… Bolla et al (2002) found in their study that dose-dependent neurocognitive impairment persisted after 28 days of abstinence in heavy young users. Furthermore, there is also evidence that adults who initiated regular cannabis use in adolescence may have structural and functional alterations of the CNS ( Wieghorst et al, 2022 ).…”

“…• Impairment of a wide range of cognitive functions in a dose-relation manner (Broyd et al, 2016;Lorenzetti et al, 2016;Wieghorst et al, 2022) • Long-term brain functional and structural alterations (Cousijn et al, 2012;Broyd et al, 2016;Meier et al, 2022) • Sedation (Lynch and Campbell, 2011;Borgelt et al, 2013;Kuhathasan et al, 2019) Frontiers in Pharmacology frontiersin.org…”

Cannabis-based medicinal products (CBMPs) for the treatment of Long COVID symptoms: current and potential applications

“…Cognitive dysfunction is commonly reported by Long COVID patients [10]. CBD has the potential to impact brain function [79] and although CBD has been shown to improve cognition in preclinical models of cognitive impairment [80], some uncertainty remains for the potential effects of CBMPs on cognitive function due to the heterogeneity of constituents and limitations across the studies [81]. An improvement in cognition after 4 weeks of treatment with a high-CBD CBMP has been demonstrated [70] and a small clinical trial of the CBMP nabiximols in ADHD demonstrated a trend towards significance in favour of the CBMP for improving cognitive performance and activity level after 6 weeks of treatment [82].…”